147 related articles for article (PubMed ID: 10428933)
1. Quinupristin-dalfopristin is active against Toxoplasma gondii.
Khan AA; Slifer TR; Araujo FG; Remington JS
Antimicrob Agents Chemother; 1999 Aug; 43(8):2043-5. PubMed ID: 10428933
[TBL] [Abstract][Full Text] [Related]
2. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection.
Araujo FG; Khan AA; Slifer TL; Bryskier A; Remington JS
Antimicrob Agents Chemother; 1997 Oct; 41(10):2137-40. PubMed ID: 9333038
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
Ling TK; Fung KS; Cheng AF
Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of quinupristin/dalfopristin (Synercid, RP 59500) against Legionella spp.
Edelstein PH; Edelstein MA
Diagn Microbiol Infect Dis; 2000 Jan; 36(1):49-52. PubMed ID: 10744367
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of Synercid (quinupristin-dalfopristin) resistance in Gram-positive bacterial pathogens.
Kehoe LE; Snidwongse J; Courvalin P; Rafferty JB; Murray IA
J Biol Chem; 2003 Aug; 278(32):29963-70. PubMed ID: 12771141
[TBL] [Abstract][Full Text] [Related]
6. Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.
Khan AA; Lambert LH; Remington JS; Araujo FG
Antimicrob Agents Chemother; 1999 Apr; 43(4):758-62. PubMed ID: 10103177
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
8. In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
Romand S; Bryskier A; Moutot M; Derouin F
J Antimicrob Chemother; 1995 Jun; 35(6):821-32. PubMed ID: 7559193
[TBL] [Abstract][Full Text] [Related]
9. Rifapentine is active in vitro and in vivo against Toxoplasma gondii.
Araujo FG; Khan AA; Remington JS
Antimicrob Agents Chemother; 1996 Jun; 40(6):1335-7. PubMed ID: 8725996
[TBL] [Abstract][Full Text] [Related]
10. Trovafloxacin is active against Toxoplasma gondii.
Khan AA; Slifer T; Araujo FG; Remington JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1855-9. PubMed ID: 8843293
[TBL] [Abstract][Full Text] [Related]
11. Activity of natural and synthetic naphthoquinones against Toxoplasma gondii, in vitro and in murine models of infection.
Ferreira RA; Oliveira AB; Gualberto SA; Vitor RW
Parasite; 2002 Sep; 9(3):261-9. PubMed ID: 12375370
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Romand S; Della Bruna C; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.
Walzer PD; Ashbaugh A; Collins M; Cushion MT
Antimicrob Agents Chemother; 2001 Nov; 45(11):3234-7. PubMed ID: 11600389
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing.
Jamjian C; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1997 Apr; 27(4):129-38. PubMed ID: 9154409
[TBL] [Abstract][Full Text] [Related]
15. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens.
McDonald LC; Rossiter S; Mackinson C; Wang YY; Johnson S; Sullivan M; Sokolow R; DeBess E; Gilbert L; Benson JA; Hill B; Angulo FJ
N Engl J Med; 2001 Oct; 345(16):1155-60. PubMed ID: 11642231
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of Borrelia and Leptospira to Quinupristin-dalfopristin (Synercid) in vitro.
Murgia R; Cinco M
New Microbiol; 2001 Apr; 24(2):193-6. PubMed ID: 11346304
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group.
Moellering RC; Linden PK; Reinhardt J; Blumberg EA; Bompart F; Talbot GH
J Antimicrob Chemother; 1999 Aug; 44(2):251-61. PubMed ID: 10473233
[TBL] [Abstract][Full Text] [Related]
18. A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas.
Bébéar C; Bouanchaud DH
J Antimicrob Chemother; 1997 May; 39 Suppl A():59-62. PubMed ID: 9511064
[TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS determination of Synercid injections.
Abdel-Hamid ME; Phillips OA
J Pharm Biomed Anal; 2003 Aug; 32(6):1167-74. PubMed ID: 12907260
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
Speciale A; La Ferla K; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
